Condensed Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating activities
Net loss	$ (21,594,476)	$ (17,145,170)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	587,138	721,246
Accretion of interest on NuvoGen obligation	(11,467)	(12,288)
Provision for excess inventory	1,211,114	174,589
Amortization of SVB Term Loan discount and issuance costs	412,857	470,281
Stock-based compensation expense	774,160	1,317,355
Employee stock purchase plan expense	40,347	57,669
Bad debt expense	0	20,315
Non-cash operating lease expense	415,544	458,001
Accrued interest on available-for-sale securities investments	4,179	(25,018)
Gain on forgiveness of PPP Loan	0	(1,735,792)
(Gain) loss on abandonment and disposal of assets, net	(104,000)	180,008
Changes in operating assets and liabilities:
Accounts receivable	670,771	(805,736)
Inventory	140,828	(1,365,384)
Prepaid expenses and other	110,976	619,226
Accounts payable	(525,175)	453,337
Accrued liabilities	(135,890)	616,447
Contract liabilities	14,564	(38,314)
Operating lease liabilities	(419,261)	(469,326)
Net cash used in operating activities	(18,407,791)	(16,508,554)
Investing activities
Purchase of property and equipment	(23,044)	(644,381)
Proceeds from the sale of property and equipment	104,000	0
Maturities of available-for-sale securities	19,950,000	12,600,000
Purchase of available-for-sale securities	(7,610,723)	(18,620,363)
Net cash (used in) provided by investing activities	12,420,233	(6,664,744)
Financing activities
Proceeds from ATM Offering, net of commissions of approximately $0.3 million	0	10,665,819
Proceeds from March 2022 Purchase Agreement, net of issuance costs of approximately $0.5 million	7,034,049	0
Proceeds from LP Purchase Agreement	0	899,980
Payments on NuvoGen obligation	(472,625)	(530,656)
Payments on SVB Term Loan	(6,764,706)	0
Payments on SVB Term Loan Amendment issuance costs	(14,282)	0
Payments on deferred offering costs	(80,692)	0
Payments on financing leases	(16,804)	(22,563)
Proceeds from exercise of stock options	0	326
Taxes paid for net share settlement of restricted stock awards	(11,190)	(3,239)
Proceeds from shares purchased under stock purchase plans	37,567	125,828
Proceeds from Public Offering, net of commissions and issuance costs of approximately $0.9 million	9,057,857	0
Cash in lieu of fractional shares related to reverse stock split	(367)	0
Proceeds from insurance note	822,889	0
Payments on insurance notes	(990,475)	(743,873)
Net cash provided by financing activities	8,604,820	10,391,622
Effect of exchange rates on cash	(6,355)	(16,186)
Increase (decrease) in cash and cash equivalents	2,610,907	(12,797,862)
Cash and cash equivalents at beginning of period	9,599,950	22,397,812
Cash and cash equivalents at end of period	12,210,857	9,599,950
Supplemental disclosure of noncash investing and financing activities
Fixed asset purchases payable and accrued at period end	6,238	0
Issuance costs payable and accrued at year end	350,458	0
Issuance of common stock upon conversion of Series A convertible preferred stock	1,402,430
Issuance of common stock from cashless exercise of pre-funded warrants	0	12
2021 Insurance Note issued for insurance premiums	0	746,360
Gain on forgiveness of PPP Loan	0	1,735,792
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	77,385	1,302,457
Carrying value of demonstration units transferred from property and equipment to inventory	0	16,128
Disposal of fully depreciated assets	1,075,715	635,870
Reclassification of instrument from inventory to property and equipment	36,976	0
Supplemental cash flow information
Cash paid for interest	477,625	599,922
Cash paid for taxes	8,973	12,665
March Two Thousand Twenty Two Purchase Agreement [Member]
Financing activities
Proceeds from exercise of pre-funded warrants	2,411	0
December Two Thousand Twenty Two secuirities purchase agreement [Member]
Financing activities
Proceeds from exercise of pre-funded warrants	$ 1,188	$ 0